Claims for Patent: 10,543,273

Summary for Patent: 10,543,273

Title:	Anti-fibroblastic fluorochemical emulsion therapies
Abstract:	The present invention is directed to compositions and methods targeting tissue resident cells, such as fibroblasts, in a subject harboring conditions or at risk for conditions that would benefit from anti-fibroblastic therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent delivered in combination with the fluorochemical composition.
Inventor(s):	McLeay; Matthew T. (Omaha, NE)
Assignee:
Application Number:	15/144,418
Patent Claims:	1. A method of inhibiting the activity of a fibroblast cell comprising contacting the fibroblast cell with a fluorochemical composition, wherein the fluorochemical composition comprises: a. a fluorochemical; b. a bioactive agent, wherein the bioactive agent is a tyrosine-kinase inhibitor based agent; and c. an emulsion agent, wherein the emulsion agent is selected from the group consisting of triperfluoroalkylcholate, perfluoroalkylcholestanol, perfluoroalky loxymethylcholate, C3F7 O(CF2)3C(.dbd.O)NH(CH2)3N(O)(CH3)2 (XMO-10), fluorinated polyhydroxylated surfactants, polyoxyethylene-polyoxypropylene copolymers, and combinations thereof. 2. The method of claim 1, wherein the fluorochemical composition further includes an antibody. 3. The method of claim 2, wherein the tyrosine-kinase inhibitor is selected from the group consisting of afatinib, axitinib, bafetinib, bosutinib, cediranib, crizotinib, dasatinib, erlotinib hydrochloride,gefitinib, imatinib, lapatinib, lestaurtinib, neratinib, nilotinib, nintedanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sunitinib tofacitinib, vandetanib, vatalanib, and combinations thereof. 4. The method of claim 2, wherein the antibody is selected from the group consisting of alemtuzumab, bevacizumab, cetuximab, gemtuzumab ozogamicin, ibritumomab tiuxetan, ofatumumab, panitumumab, rituximab, tositumomab, trastuzumab, trastuzumab DM1, and combinations thereof. 5. The method of claim 1, wherein the fluorochemical composition bioactive agent further comprises an imaging agent. 6. The method of claim 1, wherein the fluorochemical is selected from the group consisting of bis(F-alkyl) ethanes, cyclic fluorocarbons, perfluorinated amines, brominated perfluorocarbons, perfluorooctyl chloride, perfluorooctyl hydride, perfluoroalkylated ethers, perfluoroalkylated polyethers, fluorocarbon-hydrocarbon compounds, and combinations thereof. 7. A method of inhibiting the activity of a fibroblast cell comprising contacting the fibroblast cell with a fluorochemical composition, wherein the fluorochemical composition is an aerosol and comprises (a) a perfluorocarbon; (b) tyrosine-kinase inhibitor; and (c) an emulsifier comprising 1% to 6% (w/v) phospholipid. 8. The method of claim 7, wherein the phospholipid is selected from the group consisting of lecithin, egg yolk phospholipids, and combinations thereof. 9. The method of claim 7, wherein the nonionic surfactant is selected from the group consisting of polyoxyethylene-polyoxypropylene copolymers, and combinations thereof. 10. A method of treating cancer in a subject comprising administering a fluorochemical composition to the subject in need thereof, wherein the fluorochemical composition comprises a fluorochemical, a bioactive agent that affects tyrosine-kinase activity, and an emulsion agent. 11. The method of claim 10, wherein the fluorochemical composition is applied directly to the location of the cancer in the subject as an aerosol or as a liquid. 12. An aerosolized fluorochemical composition comprising a fluorochemical, a bioactive agent that affects tyrosine-kinase activity; and 1% to 6% (w/v) of an emulsion agent, wherein the emulsion agent is selected from the group consisting of triperfluoroalkylcholate, perfluoroalkylcholestanol, perfluoroalkyloxymethylcholate, C3F7 O(CF2)3C(.dbd.O)NH(CH2)3N(O)(CH3)2 (XMO-10), fluorinated polyhydroxylated surfactants, polyoxyethylene-polyoxypropylene copolymers, a phospholipid and combinations thereof. 13. The aerosolized fluorochemical composition of claim 12, wherein the bioactive agent that affects tyrosine-kinase activity is an antibody, a tyrosine-kinase inhibitor, or both. 14. The aerosolized fluorochemical composition of claim 12, further comprising an imaging agent. 15. The aerosolized fluorochemical composition of claim 13, wherein the fluorochemical is 1-bromo-heptadecafluoro-octane. 16. The aerosolized fluorochemical composition of claim 13, wherein the emulsion agent is an egg yolk phospholipid.

Details for Patent 10,543,273

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2030-07-01
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2030-07-01
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2030-07-01
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2030-07-01
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2030-07-01
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004		2030-07-01
Acrotech Biopharma Llc	ZEVALIN	ibritumomab tiuxetan	Injection	125019	02/19/2002		2030-07-01